Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds

MLA

CTI Kuball, et al. Gamma Delta TCR Anti-CD3 Bispecific Molecules (GABs) as Novel Immunotherapeutic Compounds. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432117235&authtype=sso&custid=ns315887.

APA

CTI Kuball, Infection & Immunity, Cancer, CTI Sebestyen, Poli Van Creveldkliniek Medisch, CTI Beringer, Hematologie ICAT, CTI Straetemans, MS Hematologie, Regenerative Medicine and Stem Cells, Van Diest, E., Hernández López, P., Meringa, A. D., Vyborova, A., Karaiskaki, F., Heijhuurs, S., Gumathi Bormin, J., Van Dooremalen, S., Nicolasen, M. J. T., … Kuball, J. (2021). Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds.

Chicago

CTI Kuball, Infection & Immunity, Cancer, CTI Sebestyen, Poli Van Creveldkliniek Medisch, CTI Beringer, Hematologie ICAT, et al. 2021. “Gamma Delta TCR Anti-CD3 Bispecific Molecules (GABs) as Novel Immunotherapeutic Compounds.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1432117235&authtype=sso&custid=ns315887.